Compare CMT & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMT | PEPG |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | 1239 | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.8M | 207.1M |
| IPO Year | 1996 | 2022 |
| Metric | CMT | PEPG |
|---|---|---|
| Price | $23.89 | $3.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $24.00 | $11.17 |
| AVG Volume (30 Days) | 19.5K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $284,290,000.00 | N/A |
| Revenue This Year | $4.58 | N/A |
| Revenue Next Year | $6.04 | N/A |
| P/E Ratio | $89.48 | ★ N/A |
| Revenue Growth | ★ 5.49 | N/A |
| 52 Week Low | $16.60 | $1.30 |
| 52 Week High | $28.69 | $7.80 |
| Indicator | CMT | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 63.42 |
| Support Level | $22.80 | $1.47 |
| Resistance Level | $25.38 | $3.57 |
| Average True Range (ATR) | 1.10 | 0.21 |
| MACD | -0.22 | -0.03 |
| Stochastic Oscillator | 26.38 | 41.01 |
Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.